J.P. Morgan Lowers Abbott Labs to Underweight

Analyst Michael Weinstein thinks the drugmaker's top seller, Biaxin, will be hurt by generic competition

J.P. Morgan downgraded Abbott Laboratories (ABT ) to underweight from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.